Furthermore, since the SYK pathway seems to be upregulated in AML cells [4], it is likely that SYK inhibitors, like most other tyrosine kinase inhibitors, have limited effects on normal hematopoietic cells and, hence, hematological toxicity. Here, SYK is linked to acute myeloid leukemia.